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Abstract: Thrombosis, the localized clotting of blood, occurs in both the arterial and venous 
circulation, and has a major impact on health outcomes. The primary etiology of myocardial 
infarctions, and approximately 80% of strokes, is acute arterial thrombosis. In combination this 
represents the most common cause of death in the Western world, while the third leading cause of 
cardiovascular-associated death is venous thromboembolism. An understanding of the pathogenic 
changes in the vessel wall and the blood that result in thrombosis is crucial for developing safer 
and more effective antithrombotic drugs. Dabigatran etexilate belongs to a new class of direct 
thrombin inhibitors. Following oral administration, dabigatran reaches peak plasma concentrations 
within 2 hours, shows linear pharmacokinetics, and a limited (but important) amount of direct 
drug interactions. Given once daily at 150 mg or 220 mg, it has proven to be competitive with 
enoxaparin in the prevention of venous thromboembolism after major orthopedic surgery, with 
a comparable safety profile. For stroke prevention in patients suffering from atrial fibrillation, 
dabigatran administered at a dose of 110 mg twice daily was associated with rates of stroke and 
systemic embolism that were similar to those associated with warfarin, as well as lower rates of 
hemorrhage. Dabigatran given at a dose of 150 mg twice daily, as compared with warfarin, was 
associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. 
Oral bioavailability of dabigatran, together with a rapid onset and offset of action and predictable 
anticoagulation response, makes this newly available antithrombotic drug an attractive alternative 
to traditional anticoagulant therapies for numerous thrombosis-related indications.
Keywords: dabigatran etexilate, anticoagulation, direct thrombin inhibitors, thrombosis, 
prevention
Indications for anticoagulant therapy
Thrombosis, the formation of a blood clot within a blood vessel or cavity of the heart, 
is a leading cause of death and disability. Up to 15% of patients hospitalized for an 
acute medical illness develop venous thromboembolic disease and some of them suf-
fer from serious and life-threatening complications such as pulmonary embolism.1 
Thromboemboli are blood clots moving through the bloodstream, which may lodge 
in a vessel and block circulation. The following paragraph summarizes the major 
indications for anticoagulant therapy and address specific complications and common 
limitations of current therapeutic regimens.
Venous thromboembolic disease
Although many associate venous thrombosis with recent trauma or surgery, 50% to 70% 
of symptomatic cases, as well as the majority of cases of fatal pulmonary embolism (PE), Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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occur in medical patients.2 Due to the often silent nature of 
venous thrombosis, the first sign of a problem may be a clini-
cally significant complication, such as PE. Cancer and other 
medical illness are major contributors to venous thromboem-
bolism (VTE) risk.3 Hospitalized patients, especially the ones 
in critical care settings, are often immobile or even bedridden. 
Even in the absence of medical illness, lack of mobility can lead 
to venous stasis and VTE, as can occur during long-distance 
air travel.4 Table 1 presents common conditions and patient-
related, predisposing characteristics that are associated with 
hospitalization and an increased risk for VTE. Age, in particu-
lar, is one of the most important risk factors for VTE.1
Prospective studies have shown that hospitalized medical 
patients at high risk who do not receive preventive antico-
agulant therapy develop isolated calf thrombosis in 10% to 
15% of cases. The same studies revealed an incidence of 
proximal deep vein thrombosis (DVT) in 2% to 5% and of 
PE in 0.3% to 1.5%.5,6
Studies have also shown that anticoagulant prophylaxis 
reduces the risk of symptomatic VTE in hospitalized medi-
cal patients.7 Despite the clear need for prophylactic care to 
prevent VTE in high-risk medical patients, a recent multina-
tional, cross-sectional report3 revealed that fewer than 40% of 
hospitalized medical patients at risk received standard VTE 
prophylaxis. Therefore, timely risk assessment and preven-
tive therapy is crucial.
In addition to the acute risk of PE, a potentially life-
threatening event, venous thrombosis also poses risks of 
intermediate- and long-term complications that include 
recurrent DVT, post-thrombotic syndrome, and chronic 
thromboembolic pulmonary hypertension.
Recurrent DVT
The risk of recurrent DVT varies depending on the initial 
treatment. With no treatment, about half of the patients with 
symptomatic proximal DVT or PE experience a recurrence 
within 3 months.8 When proximal DVT is treated with at 
least 3 months of effective anticoagulation, the recurrence 
rate decreases considerably to 4%. Further duration of treat-
ment is strongly dependant on the etiology of the thrombosis 
(idiopathic vs secondary). Indefinite anticoagulation might 
be required for unexplained cases of recurrent DVT.9
Post-thrombotic syndrome
Between 20% and 50% of those who develop DVT eventu-
ally develop a condition known as post-thrombotic syndrome 
(PTS).10 The exact cause of PTS is not well understood, but 
it may involve damage to venous valves, ultimately leading 
to increased intravenous pressure.11 The main symptom is 
chronic pain. Signs of PTS include swelling, discoloration of 
the affected leg, and in severe cases, skin ulceration. PTS is not 
reliably prevented by prompt antithrombotic therapy following 
the diagnosis of DVT. This is another reason why preventive 
therapy is the optimal approach for high-risk patients.12
Chronic thromboembolic pulmonary hypertension
Pulmonary hypertension occurs as a late complication in 
between 3% and 4% of patients who survive pulmonary 
  embolism.13 Symptoms include progressive shortness of breath 
and exercise intolerance. Later in the course of the disorder, 
chest pain with exertion and syncope may occur. Without 
intervention, the 5-year survival rate once the mean pulmonary 
artery pressure has reached 40 mmHg is about 30%.14
Atrial fibrillation and stroke prevention
Atrial fibrillation (AF) is the most common sustained 
arrhythmia seen in clinical practice, affecting an estimated 
4.5 million people in the European Union and 2.2 million 
Americans.15 AF is associated with a major risk of stroke, 
caused by thrombus formation within the left atrium and 
embolization to the cerebral arteries. The degree of stroke 
risk and the need for anticoagulant therapy to lower this risk 
varies among patients with AF.
The prevalence of this arrhythmia increases sharply with 
older age. AF is uncommon among individuals #50 years 
old.16 In the Framingham Heart Study, the percentage risk 
Table 1 Common conditions and patient-related predisposing 
characteristics associated with hospitalization and increased risk 
for VTe
Conditions associated  
with hospitalization that 
increase risk of VTe
previous stroke
congestive heart failure (NYHA Class iii–iV) 
acute respiratory disease  
acute myocardial infarction  
acute arthritis  
acute infection  
inflammatory bowel disease
Patient-related  
predisposing  
characteristics that  
increase risk of VTe
recent surgery or major trauma 
immobility or paralysis  
malignancy  
previous VTe  
older age (.80 years)  
estrogen therapy (contraceptives or 
hormone replacement)  
obesity  
central vein catheterization  
varicose veins  
inherited or acquired thrombophilia.
Abbreviations:  VTe,  venous  thromboembolism;  NYHA,  New  York  Heart 
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of stroke ascribable to AF rose from 1.5% in the age group 
50 to 59 years, to 23.5% in the age group 80 to 89 years. 
The median age of patients with AF is 72 years.17 Worldwide 
population trends of increasing life expectancy and increasing 
prevalence of selected risk factors for AF indicate a worsen-
ing epidemic.18 Overall, AF accounts for about 15% of all 
strokes in the United States.16 The rate of ischemic stroke 
among AF patients included in clinical primary prevention 
trials and not treated with antithrombotic therapy averaged 
4.5% per year, similar to estimates of stroke risk from the 
Framingham Heart Study. Further analyses from these studies 
indicate that the lifetime risk of AF for an individual age 40 
years is about 25%.19 AF is more prevalent in men than in 
women at all ages. The prevalence of AF may actually be even 
higher, given the potential for AF to remain undiagnosed.20
AF raises the risk of ischemic stroke by a factor of four 
to five, thought to be predominately the result of cardiogenic 
t  homboembolism.21 This is based on clinical assessments, on 
operative findings of intracardiac thrombus in patients with rheu-
matic mitral valve disease, and more recently, on transesopha-
geal echocardiography imaging of thrombus in the left atrium 
of patients with AF, mainly in the left atrial appendage.16
Given the epidemiologic characteristics of AF and the 
importance of stroke as a leading cause of death and dis-
ability, multiple large-scale, randomized trials have been 
completed and are under way to find efficacious and relatively 
safe ways to reduce the risk of ischemic stroke and other 
systemic thromboembolic events related to AF.
Acute coronary syndrome
Acute coronary syndrome (ACS) occurs when an athero-
sclerotic plaque ruptures, leading to thrombus formation 
within a coronary artery. Patients who develop symptoms 
consistent with ACS, such as chest pain and diaphoresis, 
require timely evaluation to determine the cause. When ACS 
is diagnosed, further stratification into categories of ST-
elevation myocardial infarction (STEMI), non-ST-elevation 
myocardial infarction (NSTEMI), and unstable angina guides 
therapeutic decision-making.22 Following recovery from an 
episode of ACS, patients continue to be at heightened risk 
of heart attack and stroke, for which a range of secondary 
preventive treatments are available.23
Mechanical heart valve recipients
Optimal anticoagulation management in patients after 
mechanical heart valve replacement is still an unresolved 
issue. Vitamin K antagonists (VKAs) represent the standard 
of care for long-term prophylaxis after mechanical heart valve 
replacement. Nevertheless, thromboembolic events occur in 
approximately 2% to 5% of these patients per year despite 
oral anticoagulation (OAC).24 The incidence of   bleeding 
complications correlates with VKA dosage, and such com-
plications have been observed within the range of 2% to 9% 
annually.25 Thromboembolism and anticoagulant-related 
bleeding account for ≈75% of all complications experienced 
by heart valve recipients.26 They occur in particular in patients 
with mechanical heart valves in need of invasive or surgi-
cal procedures when the antithrombotic therapy is switched 
from VKAs to heparins or vice versa.26,27 Therefore, it is 
important to find alternative approaches for the prophylaxis of 
thromboembolic complications after mechanical heart valve 
replacement that are associated with fewer bleeding events.
Benefits and limitations of current 
anticoagulation regimen
While most current anticoagulant drugs (Figure 1) have 
been mainstays of antithrombotic therapy for decades, many 
clinicians find these medications challenging to use. This, 
when combined with underappreciation of the degree of VTE 
risk in certain patients, has led to considerable underuse of 
preventive antithrombotic therapy in some countries. Obser-
vational studies reveal that fewer than half of the patients at 
high risk of VTE receive prophylactic treatment.2,5
A new anticoagulant that more closely meets the criteria 
for optimal antithrombotic efficacy could improve the qual-
ity of care. Such an advance also might help overcome the 
gaps between evidence-based treatment recommendations 
and clinical practice. Ideally, an anticoagulant should be 
administered orally. It should be highly effective in reduc-
ing venous thromboembolism, inhibiting both free and 
clot-bound coagulation factors, have a predictable dose 
response and kinetics, and show low, nonspecific plasma 
protein binding, resulting in a low rate of bleeding events. 
Coagulation monitoring and dose adjustment should not be 
routinely required, thus creating a wide therapeutic window. 
Furthermore, there should be only little interaction with food 
or other drugs.
Vitamin K antagonists
Antagonists of vitamin K have been used as anticoagulants 
for over 50 years. Warfarin, a synthetic derivative of cou-
marin, is the most commonly used VKA in the US. In some 
European countries, other coumarin derivatives (phenprocou-
mon and acenocoumarol) are used instead.28
With appropriate dosing, these medications effectively 
inhibit coagulation and have been shown to substantially Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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reduce the risk of stroke in AF and the likelihood of 
  recurrence in VTE.29 However, VKAs are limited by a nar-
row therapeutic window, with a resultant need for frequent 
monitoring and dosage adjustments. Other drawbacks of this 
class include drug and food interactions (eg, vitamin-K-rich 
foods), a well-documented incidence of major bleeding of 
1% to 3%, and delayed onset and offset of anticoagulant 
effect.28 Bleeding is the most common adverse event with 
VKAs. The incidence of major bleeding varies from less 
than 2% a year with care in an anticoagulation clinic to 4% 
to 5% a year with usual medical care.19,27
Heparins
Unfractionated heparin (UFH) has been used for the pre-
vention and treatment of thrombosis since the 1930s. Low-
molecular-weight heparins (LMWHs), derived from UFH 
by depolymerization, were introduced in Europe in the 
1980s.29 Because of several clinical advantages, LMWHs 
have gradually replaced UFH for most indications. However, 
UFH continues to be used during cardiovascular surgery and 
catheter-based interventional procedures.30
Heparins and heparinoids are parenteral agents, admin-
istered either intravenously or subcutaneously. The need for 
parenteral administration makes these agents both incon-
venient and costly for long-term use, especially outside the 
hospital setting.15
Each LMWH product has a specific molecular weight 
distribution. This distribution determines its anticoagulant 
activity, duration of action, and renal clearance, so each 
agent is considered a unique drug. Indications for LMWHs 
vary – one product cannot always be substituted for another. 
LMWHs in current use globally include enoxaparin, 
dalteparin, nadroparin, tinzaparin, certoparin, reviparin, 
parnaparin and bemiparin.31
Bleeding is the most common adverse event with 
heparin therapy. Major bleeding occurs in 0.8% of patients 
receiving full-dose UFH, but is less frequent with low-
dose subcutaneous heparin. LMWH has been reported to 
cause bleeding less frequently, but this finding has not been 
consistent across trials. Major bleeding occurs in less than 
3% of patients and varies with product, indication, patient 
population, and dose.32
Although, hemorrhage is the most common and best 
recognized complication of heparin treatment, potentially 
more dangerous is the development of heparin-induced 
thrombocytopenia (HIT), especially HIT complicated by 
Figure 1 Targets of different anticoagulant agents (indicated in colored blocking arrows) in the coagulation cascade.
Abbreviations: F, factor; LMwH, low-molecular-weight heparin; UFH, unfractionated heparin; VKA, vitamin K-antagonist.
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thrombosis   syndrome (HITTS). All patients exposed to 
heparin,   irrespective of the dose and route of administration, 
are at risk of developing HIT. This condition develops as the 
result of the formation of antibodies to the heparin-platelet 
factor 4 complex, which causes secondary activation of 
platelets, coagulation, and ultimately increased thrombin 
production.33
Danaparoid, available in several countries, is classified 
as a heparinoid. It is composed of sulfated glycosaminogly-
cans and can be used as an alternative to heparin in patients 
suffering from HIT.31
Factor Xa inhibitors
Fondaparinux, a pentasaccharide, is a synthetic indirect 
inhibitor of Factor Xa (FXa). Unlike heparin, fondaparinux 
does not inactivate thrombin or inhibit FXa bound in the 
prothrombinase complex and therefore does not completely 
inhibit FXa. Long-term use is limited by the requirement of 
subcutaneous injection.34
Bleeding is the most common adverse event with fonda-
parinux, with major bleeding occurring at about the same 
rate as seen with patients treated with LMWHs. Episodes 
of excessive bleeding due to fondaparinux may be treated 
effectively with Novoseven (recombinant coagulation 
factor VIIa).34
Orally available FXa-inhibitors, such as rivaroxaban and 
apixaban, are currently being investigated in large Phase 
II and III trials. Rivaroxaban (Xarelto®; Bayer Schering 
Pharma) is already approved for the primary prevention of 
VTE after orthopedic surgery in adults in Canada as well as 
the European Union.
Direct thrombin inhibitors
Parenteral direct thrombin inhibitors are used during percuta-
neous coronary interventions (PCIs), and to treat or prevent 
thrombosis in patients with HIT. Three such medications are 
in current clinical use – lepirudin, bivalirudin, and argatroban. 
These drugs differ with respect to thrombin binding sites, 
reversibility, pharmacology, and specific indications.35
The first oral direct thrombin inhibitor available for 
clinical use was ximelagatran. This medication represented a 
major advance over existing oral anticoagulants (eg, VKAs) 
because it did not require anticoagulant monitoring or dose 
adjustments. In clinical VTE prevention and treatment, 
ximelagatran was either more effective than or comparable 
to warfarin. However, safety monitoring revealed liver tox-
icity in 6% of patients. For this reason, use of the drug was 
discontinued in 2006.36
Advantages and disadvantages of the oral direct   thrombin 
inhibitor dabigatran etexilate will be described in the fol-
lowing sections.
Dabigatran etexilate- pharmacology, 
pharmacokinetics, and safety
Dabigatran etexilate (Pradaxa® in Europe, Pradax® in Canada; 
Boehringer Ingelheim) is a small molecule prodrug which 
does not exhibit any pharmacological activity. After oral 
administration, dabigatran etexilate is rapidly absorbed and 
converted to dabigatran by esterase-catalyzed hydrolysis in 
plasma and in the liver. The prodrug contains micropellets 
with dabigatran etexilate around a tartaric acid core, since a 
low pH is necessary for optimal drug absorption.37
Dabigatran is a potent, competitive, reversible direct 
thrombin inhibitor. Since thrombin (serine protease) enables 
the conversion of fibrinogen into fibrin during the coagulation 
cascade, its inhibition prevents the development of thrombus. 
Dabigatran also inhibits free thrombin, fibrin-bound thrombin 
and thrombin-induced platelet aggregation.38
Dabigatran prolongs the activated partial thromboplastin 
time (aPTT). In patients who are bleeding, aPTT tests may be 
useful in identifying excessive anticoagulant activity, despite 
the aPTT being less sensitive to the activity of dabigatran at 
supratherapeutic levels. If available, thrombin time and ecarin 
clotting time may be more sensitive tests to evaluate the antico-
agulant effects of dabigatran. Prothrombin time (INR, interna-
tional normalized ratio) is prolonged by dabigatran but is less 
sensitive than thrombin time and ecarin clotting time.39
After oral administration of dabigatran etexilate in 
healthy volunteers, the pharmacokinetic profile of dabiga-
tran in plasma is characterized by a rapid increase in plasma 
concentration with maximum concentration (Cmax) attained 
between 0.5 and 2.0 hours post-administration. After Cmax, 
plasma concentrations of dabigatran show a biexponential 
decline with a mean terminal half-life of 14 to 17 hours in 
young healthy volunteers, and 12–14 hours in elderly sub-
jects. The half-life is independent of dose. Food does not 
affect the bioavailability of dabigatran but delays the time 
to peak plasma concentrations by 2 hours. The absolute 
bioavailability of dabigatran following oral administration 
of dabigatran etexilate is approximately 6.5%.40
Dabigatran is eliminated largely unchanged in the urine, 
at a rate of approximately 100 mL/min corresponding to the 
glomerular filtration rate. Low (34% to 35%) concentration 
independent binding of dabigatran to human plasma proteins 
was observed. The exposure (area under the curve = AUC) 
of dabigatran after the oral administration of dabigatran Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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etexilate is approximately 2.7-fold higher in volunteers with 
moderate renal insufficiency (creatinine clearance = CrCL 
between 30 to 50 mL/min) than in those without renal insuf-
ficiency. In a small number of volunteers with severe renal 
insufficiency (CrCL 10 to 30 mL/min), the exposure (AUC) 
to dabigatran was approximately 6 times higher and the 
half-life approximately 2 times longer than that observed in 
a population without renal insufficiency.41 Specific pharma-
cokinetic studies with elderly subjects showed increases of 
40% to 60% in the exposure (AUC) and of more than 25% 
in Cmax compared to young subjects. Population-based phar-
macokinetic studies have evaluated the pharmacokinetics of 
dabigatran after repeated doses in patients (up to 88 years). 
The observed increase in dabigatran exposure (AUC) 
  correlated with age-related reductions in CrCL.41
No change in dabigatran exposure (AUC) was seen in 
12 subjects with moderate hepatic insufficiency (Child-
Pugh B) compared to 12 controls. Body weight had a minor 
effect on plasma clearance of dabigatran resulting in higher 
exposure (AUC) in patients with low body weight.42 There 
were no differences in the phase 3 clinical studies for efficacy 
and safety data between men and women. Drug exposure 
(AUC) in female patients is about 40% to 50% higher than 
in male patients, but no dose adjustment is recommended. 
Ethnic origin does not appear to affect the pharmacokinetics 
of dabigatran in a clinically relevant manner. However, no 
pharmacokinetic data in black patients are available.43
In vitro interaction studies did not show any inhibition or 
induction of the principal isoenzymes of cytochrome P450.44 
This has been confirmed by in vivo studies with healthy vol-
unteers, who did not show any interaction between this treat-
ment and atorvastatin (CYP3A4), digoxin (P-gp transporter 
interaction) or diclofenac (CYP2C9). However, dabigatran 
is not without important drug interactions. P-glycoprotein 
inhibitors (including verapamil, amiodarone, and especially 
quinidine) raise dabigatran serum concentrations consider-
ably. For example, dabigatran exposure in healthy subjects 
was increased by 60% in the presence of amiodarone.42
The population pharmacokinetic analysis of co-medication 
effects supports the use of antacids and gastric acids suppres-
sants without dose adjustment of dabigatran etexilate in patients, 
and revealed the absence of dabigatran drug interactions with 
the most commonly used drugs in the study population.43
Dabigatran etexilate in the 
prevention of deep vein thrombosis
For more than 20 years, routine preventive anticoagulant 
therapy has been the standard of care for major   orthopedic 
surgery. Despite the well-recognized risks of VTE in 
  hospitalized patients, there remains a low rate of appropriate 
prophylaxis.5
Major orthopedic surgery involving the lower extremity – 
hip or knee replacement surgery or hip fracture surgery – is 
associated with a high risk of VTE. Without prophylaxis, 
rates of DVT range from 40% to 60% when assessed by 
venography 7 to 14 days after surgery. Routine ventilation-
perfusion scans in patients following hip or knee arthroplasty 
revealed pulmonary emboli in 3% to 28% of patients.3 Most 
cases of symptomatic VTE manifest after discharge from the 
hospital, and are the most common reason for readmission 
following orthopedic procedures.1,5
Patients who have had total hip replacement and no VTE 
by venography at discharge continue to be at risk of late-onset 
VTE up to 35 days after surgery.2 Current recommendations 
regarding the duration of anticoagulation treatment following 
hip and knee surgery are based on this understanding of the 
chronology of VTE.7
In 2 large randomized, parallel group, double-blind, dose-
confirmatory trials,45,46 patients undergoing elective major 
orthopedic surgery (one for knee replacement surgery and 
one for hip replacement surgery) received dabigatran etexilate 
75 mg or 110 mg within 1 to 4 hours of surgery followed 
by 150 or 220 mg daily thereafter, hemostasis having been 
secured, or enoxaparin 40 mg on the day prior to surgery and 
daily thereafter. In the RE-MODEL trial (knee replacement) 
treatment was for 6 to 10 days and in the RE-NOVATE trial 
(hip replacement) for 28 to 35 days. Totals of 2076 patients 
(knee) and 3494 (hip) were treated respectively. The results 
of RE-MODEL with respect to the primary end-point, total 
VTE including asymptomatic DVT plus all-cause mortal-
ity, showed that the antithrombotic effect of both doses of 
dabigatran etexilate were statistically non-inferior to that of 
enoxaparin. Similarly, total VTE including asymptomatic 
DVT and all-cause mortality constituted the primary end-
point for RE-NOVATE. Again dabigatran etexilate at both 
daily doses was statistically non-inferior to enoxaparin 
40 mg daily.
However, non-inferiority was not established in a third 
  randomized, parallel group, double-blind trial (RE-  MOBILIZE), 
in which patients undergoing elective total knee surgery 
received dabigatran etexilate 75 mg or 110 mg within 6 to 
12 hours of surgery followed by 150 mg and 220 mg daily 
thereafter. The treatment duration was 12 to 15 days. In 
total 2615 patients were randomized and 2596 were treated. 
The comparator dosage of enoxaparin was 30 mg twice 
daily according to common recommendations in the US. Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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There were no statistical differences in bleeding between 
the   comparators.47 Mostly due to these findings dabigatran 
etexilate did not get approved for treatment in North America 
at this point by the US Food and Drug Administration.
A randomized, parallel group, double-blind, placebo-
controlled phase II study in Japanese patients48 in which 
dabigatran etexilate was administered at 110 mg, 150 mg, 
and 220 mg the day after elective total knee replacement 
surgery, showed a clear dose response relationship for the 
efficacy of dabigatran etexilate and a placebo like bleeding 
profile. In RE-MODEL and RENOVATE the randomization 
to the respective study medication was done pre-surgery, and 
in the RE-MOBILIZE and the Japanese trial the randomiza-
tion was performed post-surgery. This is of note especially 
in the safety evaluation of these trials.
In the recently published RE-COVER trial, dabigatran 
etexilate (150 mg twice daily) was as effective and safe as 
warfarin (adjusted INR of 2.0 to 3.0) in patients suffering 
from acute VTE.49 Further studies are currently recruiting 
patients to investigate the efficacy and safety of dabiga-
tran in the prevention of secondary VTE (RE-MEDY and 
RE-SONATE).
Dabigatran etexilate in stroke 
prevention and management  
of atrial fibrillation
Cardioembolic stroke is one of the main complications of 
AF, and occurs when stagnant blood in the fibrillating atrium 
forms a thrombus that then embolizes to the cerebral circula-
tion, blocking arterial blood flow and causing ischemic injury. 
The incidence of stroke in patients with nonvalvular AF is 
between 2- and 7-fold greater than in the general population. 
For patients with AF caused by valvular disease, the risk of 
stroke increases 17-fold.50
A systematic review of 6 cohorts of AF patients identi-
fied three other independent risk factors in addition to age: 
prior history of stroke or transient ischemic attack, history 
of hypertension, and diabetes.51 Several scoring systems are 
available to help clinicians estimate the stroke risk in AF. 
One popular, well-validated risk assessment tool is the 
CHADS2-Score (Table 2).52
The recently presented RE-LY trial,53 which compared 
two fixed doses of dabigatran etexilate (110 mg and 150 mg) 
administered twice daily to warfarin, has major implications 
for prevention of stroke, thromboembolic complications, 
and life-threatening hemorrhagic complications. The trial 
randomly assigned 18113 patients who had AF and a con-
comitant risk of stroke. Rates of the primary outcome (stroke 
or systemic embolism) were 1.69% per year in the warfarin 
group compared with 1.53% per year in the group that 
received 110 mg of dabigatran (relative risk with dabigatran, 
0.91; 95% confidence interval [CI] 0.74 to 1.11; P , 0.001 
for non-inferiority), and 1.11% per year in the group that 
received 150 mg of dabigatran (relative risk, 0.66; 95% CI 
0.53 to 0.82; P , 0.001 for superiority).
The rate of major bleeding was 3.36% per year in the 
warfarin group, as compared with 2.71% per year in the group 
receiving 110 mg of dabigatran (P = 0.003) and 3.11% per 
year in the group receiving 150 mg of dabigatran (P = 0.31). 
Further, the rate of hemorrhagic stroke was 0.38% per year 
in the warfarin group, compared with 0.12% per year with 
110 mg of dabigatran (P , 0.001) and 0.10% per year with 
150 mg of dabigatran (P , 0.001).
No real advantage was seen in mortality rate, which was 
4.13% per year in the warfarin group, 3.75% per year with 
110 mg of dabigatran (P = 0.13) and 3.64% per year with 
150 mg of dabigatran (P = 0.051).
In sum, dabigatran administered at a dose of 110 mg twice 
daily was associated with rates of stroke and systemic embo-
lism that were similar to those seen with warfarin, but with 
lower rates of hemorrhage, while dabigatran at 150 mg twice 
daily was associated with lower rates of stroke and systemic 
embolism but similar rates of major hemorrhage.
Likely due to the controlled trial setting, the rate of 
bleeding in the warfarin group was slightly lower (3.36% per 
year) than is usually seen in real-world ambulatory care of 
Table 2 CHADS2 score
C: Congestive heart failure  = 1 point
H: Hypertension (systolic .160 mmHg)  = 1 point 
A: Age .75 years  = 1 point 
D: Diabetes  = 1 point
S: Prior transient ischemic attack or stroke  = 2 points
CHADS2 score Adjusted stroke ratea (%) 
(95% confidence interval)
0 1.9 (1.2–3.0)
1 2.8 (2.0–3.8)
2 4.0 (3.1–5.1)
3 5.9 (4.6–7.3)
4 8.5 (6.3–11.1)
5 12.5 (8.2–17.5)
6 18.2 (10.5–27.4)
Notes: The annual stroke rates for patients suffering from AF according to the 
CHADS2 Score. Patients with a CHADS2 Score of 0 are considered to have a low 
risk for cardioembolic stroke. Patients with a score of 1–2 are classified as having 
a moderate risk for stroke and should be medically treated with an antithrombotic 
agent. Patients with a score of 3 or higher have a high risk for thromboembolic 
complications and require optimal antithrombotic treatment as well.
aThe adjusted stroke rate is the expected stroke rate per 100 person-years derived 
from the multivariable model assuming that aspirin is not taken.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  anticoagulated patients. It is possible that, if used in patients 
outside of a clinical trial, bleeding complications will occur 
even more infrequently with dabigatran than with warfarin.
Surprisingly, the annualized rates for myocardial infarc-
tion (MI) were 0.72% for low-dose dabigatran, 0.74% for 
high-dose dabigatran, and 0.53% for warfarin. The risk 
trended higher for low-dose dabigatran at 1.35 (95% CI 0.98 
to 1.87; P = 0.07) and was significantly higher for in the high-
dose group at 1.38 (95% CI 1.00 to 1.91; P = 0.048). This 
somewhat unexpected finding leads to the hypothesis that 
warfarin is more effective in reducing MI than dabigatran 
at this particular aspect of antithrombotic therapy. However, 
the absolute rates of MI were quite low, and the effect of 
dabigatran in reducing stroke and intracerebral bleedings far 
outweighed the small increase in MI rate.
Rates of dyspepsia (including abdominal pain) were 
increased with dabigatran (11.8% in the 110-mg group and 
11.3% in the 150-mg group) as compared with warfarin 
(5.8%), and it may have contributed to the greater second-year 
rate of dropout in patients taking dabigatran (approximately 
21%) as compared with warfarin (16.6%).54
Prospective indications  
for dabigatran etexilate
Mechanical heart valve thrombosis
Lifelong OAC therapy is required for the prevention of 
thromboembolic events after implantation of an artificial 
heart valve. Thromboembolism and anticoagulant-related 
bleedings account for ≈75% of all complications experi-
enced by heart valve recipients (2% to 9% of patients per 
year). In preparation for surgical procedures, OAC treat-
ment must be interrupted. The gold standard for adjusting 
oral to parenteral anticoagulation treatment in patients at a 
high risk for developing thromboembolic complications is 
intravenous administration of UFH,25,26 which needs to be 
continuously infused to ensure an adequate effect. However, 
anticoagulation with UFH is associated with an increased 
rate of complications. These complications are related to low 
bioavailability, short half-life, platelet activation, and inter-
individual differences regarding optimal dosage of UFH.27 
Although most guidelines favor intravenous administration 
of UFH, LMWH (eg, enoxaparin, dalteparin, and tinzaparin) 
represent an additional option for bridging therapy.25,26
A new anticoagulant that more closely meets the criteria 
for optimal antithrombotic efficacy could improve the qual-
ity of care. Such an advance also might help overcome gaps 
between evidence-based treatment recommendations and 
clinical practice.
Studies in patients with a strong indication for anti-
coagulant therapy because of high thromboembolic risk 
without adequate protection, such as patients with a 
mechanical heart valve, are not scheduled in the early phase 
of development of new antithrombotics. Inappropriate dos-
ing would lead to unacceptable outcomes in this high-risk 
population. A new agent such as dabigatran etexilate could 
be a welcome addition for improving care in these patients. 
Future prospective and randomized studies in humans should 
address the question of whether orally administered dabiga-
tran etexilate is as effective as UFH, LMWH, and VKAs in 
preventing thrombus formation on mechanical heart valves. 
Notably, large, randomized, prospective trials are also lack-
ing for LMWH as regards prevention of mechanical heart 
valve thrombosis.
Less thrombogenic materials and improved valve and 
hinge designs may reduce the propensity for thrombus forma-
tion and the need for aggressive anticoagulation. This might 
reverse the present trend to increased use of bioprosthetic 
valves.55 The step from preclinical in vitro and in vivo testing 
to widespread clinical use is hampered by the lack of good 
predictive animal models and always entails a certain risk.
Acute coronary syndrome and 
percutaneous coronary intervention
Risk assessment is a key step in the emergency management 
of patients with ACS. Stratifying patients by likelihood of 
morbidity and mortality guides management decisions. 
A range of risk-scoring systems have been devised to enable 
clinicians to select the appropriate antithrombotic, antiplatelet 
and/or fibrinolytic therapy.27
Patients with complete occlusion of a coronary artery 
can often be identified by ST-segment elevation on elec-
trocardiogram. This group, representing approximately 
one in three patients presenting with ACS, should receive 
prompt reperfusion treatment with fibrinolytic therapy or 
PCI. The remaining two-thirds of ACS patients do not have 
ST-segment elevation on initial ECG, and require further 
risk stratification.22
Because atherosclerotic plaque is often present through-
out the arterial tree, patients who survive an episode of ACS 
live with an ongoing risk of a recurrent acute cardiovascular 
event, such as MI, sudden cardiac death, or stroke.56 For 
patients who receive a stent during revascularization, there 
is an additional risk of in-stent thrombosis.22
A wide range of treatments are available to protect the 
heart and to decrease the propensity for recurrent athero-
thrombosis in survivors of ACS. Antiplatelet agents such as Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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ASA and clopidogrel are used for up to 12 months after ACS 
to prevent a recurrent event.22 For immediate antithrombotic 
therapy a wide range of agents are available. So far all of 
them need to be administered intravenously. DTIs currently 
available for intravenous administration that are successfully 
and primarily used in the treatment of HIT as well as PCI are 
lepirudin, bivalirudin, and argatroban.57 DTIs are potentially 
ideal agents for PCI and ACS patients due to their antithrom-
botic and antiplatelet properties.
Dabigatran is currently being studied in a randomized, 
open-label phase-II trial in patients undergoing elective PCI 
(ClinicalTrials.gov Identifier: NCT00818753). The purpose 
of the study is to assess whether two doses of dabigatran etexi-
late (110 mg twice daily and 150 mg twice daily) compared 
with UFH, both in addition to a standard dual antiplatelet 
regimen, provide sufficient anticoagulation in the setting of 
elective PCI.
Currently usage of VKAs in patients after ACS has very 
limited indications as an add-on therapy to antiplatelet drugs 
such as clopidogrel and aspirin. These indications include 
patients with AF and at high risk for stroke, mechanical 
heart valve recipients, and patients with a left ventricular 
aneurysm and/or thrombus formation in the left ventricular 
cavity. Triple therapy with antiplatelet drugs and VKAs is 
associated with a high risk of bleeding. The frequency of such 
events in reported series varies, with up to 21% of patients 
needing a transfusion. Bleeding events typically involve the 
gastrointestinal tract.58 Evidence suggests that this frequency 
increases with longer duration of triple therapy, which 
directly correlates with bleeding risk and might influence 
mortality in follow-up after PCI. In particular, the relative 
risk of major bleeding in patients receiving triple therapy is 
3- to 5-fold higher than that observed in patients receiving 
dual antiplatelet therapy alone. The increase in bleeding 
events is confounded by the fact that patients receiving triple 
therapy are typically older and have multiple co-morbidities. 
Limited use of triple therapy (for 1 month) is associated with 
at least a 2-fold lower risk of major bleeding compared with 
prolonged use ($6 months).58 Dabigatran etexilate may have 
a role as an acceptable substitute for VKAs in these high risk 
patients, but this has not yet been studied.
Conclusions
Recent advances in antithrombotic therapy have the poten-
tial to significantly affect the management of patients with 
thromboembolic disease and disease risk. The development 
of new orally available agents has already changed the field of 
anticoagulation beyond the once gold standard of VKAs, and 
will undoubtedly result in a paradigm shift in the management 
of these diseases. Warfarin has proven to be very effective for 
the primary prevention of stroke and AF, as well as for the 
long-term management of patients with a whole spectrum 
of thromboembolic-related illnesses. However, its significant 
limitations have been discussed throughout the review.
These limitations have led to a search for new anticoagu-
lant drugs, a quest made easier by improved understanding 
of coagulation and targeted inhibition of specific coagula-
tion factors. Not surprisingly, since FXa is the key coagula-
tion factor lying at the crossroads of intrinsic and extrinsic 
coagulation, a significant interest exists in developing drugs 
which specifically target activated FXa. Moreover, the inhibi-
tion of thrombin may be the most efficient way of inhibiting 
coagulation, giving rise to the development of drugs which 
specifically target it.59 Although it is currently not clear 
which mechanism will give rise to better clinical outcomes, 
both FXa and thrombin are likely to be excellent targets for 
inhibition with new anticoagulant drugs.
FXa inhibition appears to be the more promising avenue, 
as Factor X has fewer functions outside coagulation compared 
with thrombin. Also, Factor X is associated with a shallower 
dose response curve, suggesting that Xa inhibitors may have 
a wider therapeutic window compared to thrombin inhibitors. 
In contrast, thrombin inhibitors may allow other actions of 
thrombin to occur, such as activation of the anti-coagulant 
protein C.60
New oral anticoagulants that are currently in advanced 
stages of clinical trials offer the potential to revolutionize 
long-term anticoagulant therapy. Besides dabigatran etexilate 
these agents are rivaroxaban, apixaban, and edoxaban, all 
of which inhibit FXa.
Dabigatran etexilate has proven to be a competitive 
antithrombotic. Potential drawbacks of the drug include the 
higher occurrence of MIs in the RELY study (in comparison 
to warfarin), the inferiority compared to the North American 
enoxaparin regime in the RE-MOBILIZE study, as well as 
the lack of a readily available antidote or an established 
anticoagulant monitoring for the detection of a potential 
non-compliance in standard clinical practice. So far recom-
mendations for dabigatran use in special populations, like 
renal impairment or failure and application during preg-
nancy, are also missing. One has to be cautious to only use 
dabigatran etexilate in the currently approved indication in 
the European Union and Canada, the primary prevention of 
VTEs in adults after elective total hip or knee replacement 
surgery. Further approvals for other countries as well as other 
indications are pending.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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A drug that will prevent coagulation without   promoting 
bleeding has yet to be found. However, molecules that con-
tribute to thrombosis continue to be identified, and these 
could be new targets for the next generation of antithrom-
botic therapy. More immediately, recent studies of new 
antiplatelet drugs (such as prasugrel) and new anticoagulant 
drugs (such as dabigatran etexilate) suggest that more options 
will soon be available for the treatment of thrombosis. Fur-
thermore, the ability to identify patients at increased risk of 
thrombosis by measuring the concentrations of circulating 
factors, such as tissue factor, might allow more effective 
use of prophylaxis. Finally, “personalized medicine” is 
on the horizon, which could allow customized dosing of 
antithrombotic drugs rather than the current “one dose fits 
all” strategy.
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